New Immune-Boosting drug enters first human trials for Tough-to-Treat cancers
NCT ID NCT04855435
Summary
This is a first-in-human study to find a safe dose of a new drug called MBS8 for people with advanced solid tumors that have stopped responding to standard treatments. The trial will test the drug alone and in combination with an existing immunotherapy in specific groups of melanoma patients. The main goal is to understand the drug's safety and how the body processes it, while also looking for early signs that it might help control the cancer.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ADVANCED SOLID TUMOR are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Centro Integral Oncológico Clara Campal (CIOCC)
RECRUITINGMadrid, 28050, Spain
Contact
-
Consorcio Hospital General Universitario de Valencia
NOT_YET_RECRUITINGValencia, Spain
Contact
-
Fundacion Instituto de Investigacion Sanitaria Fundacion Jimenez Diaz (FJD)
RECRUITINGMadrid, 28015, Spain
Contact
-
Herlev and Gentofte Hospital, Center for Cancer Research
RECRUITINGHerlev, DK-2730, Denmark
Contact
-
Institut Catalá de Oncologia - Hospital Duran i Reynals.
NOT_YET_RECRUITINGBarcelona, Spain
Contact
Conditions
Explore the condition pages connected to this study.